A Phase 1 interventional study of TAK-653 Placebo and TAK-653 in Depressive Disorder, sponsored by Neurocrine Biosciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Neurocrine Biosciences · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Depressive Disorder with a site in United Kingdom — 4 open to participants now, 4 under way, 2 of them phase 3. Depressive Disorder · United Kingdom.
Among the 42 studies in Depressive Disorder with a site in United Kingdom, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2015, is one of 11 in phase 1, and was the 18th registered.
855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.
Browse Depressive Disorder studies →4 of the 42 studies in Depressive Disorder with a site in United Kingdom are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18–75
King's College London · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 18–40 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is close to the median of 88 across 689 interventional studies indexed under Depressive Disorder.
Median enrollment 58 across the 34 interventional studies, 19,469 across the 7 observational. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 42 have an industry lead sponsor. The 10 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
Neurocrine Biosciences has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies in Depressive Disorder with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06412315University of Oxford7T Amygdala and Citalopram Study | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Depressive Disorder with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of TAK-653 when administered as single and multiple oral doses at escalating dose levels in healthy participants.
The drug being tested in this study is called TAK-653. TAK-653 is being tested to treat people who have depression. This study will look at the tolerability and PK of TAK-653 in healthy participants.
The study may enroll up to 112 participants and each cohort will enroll 8 participants. This study consists of 2 parts: Part 1- single rising dose (SRD) consisting of at least 6 cohorts and Part 2- single rising dose and multiple rising dose (SRD/MRD) consisting of at least 5 cohorts. Additional cohorts may be added depending on the emerging safety and PK data. Participants will be randomly assigned (by chance, like flipping a coin) within each cohort to receive TAK-653 or placebo which will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need). Participants enrolled in Cohort 1 to 5 of Part 1 will receive TAK-653 0.3 mg, 1.0 mg, 3.0 mg, 5.0 mg and 9.0 mg or TAK-653 placebo-matching tablet. Subsequent dose escalation in Part-1, from Cohort 6 onward will occur after the full availability of safety, tolerability, PK, and PD data from preceding cohorts. Participants in Part-2 Cohorts 1 to 3 will receive TAK-653 0.3 mg, 1.0 mg and 3.0 mg respectively. Dose for Part 2, from Cohort 4 onward will be based on review of safety, tolerability, and available PK and PD data from previous cohorts. All participants will be asked to take the drug at the same time each day on Day 1 for Part 1 and Day 1 and Days 6 to 18 in Part 2.
This single-center trial will be conducted in the United Kingdom. The overall time to participate in this study is approximately 14 days for Part 1 and 31 days for Part 2. Participants will be admitted to the clinic for 6 days in Part 1 and 22 days in Part 2. Participants will be followed up 14 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional exclusion criteria for CSF collection in Cohort 3 in Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
Drug: TAK-653 Placebo · Drug: TAK-653
TAK-653 placebo-matching tablets.
TAK-653 tablets.
Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
Time frame: Baseline up to Day 14
Part 2: Percentage of Participants Who Experience at Least One TEAE
Time frame: Baseline up to Day 31
Part 1: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)
Time frame: Baseline up to Day 14
Part 2: Percentage of Participants Who Discontinued the Treatment Due to an AE
Time frame: Baseline up to Day 31
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose
Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose
Time frame: Baseline up to Day 8
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose
Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose
Time frame: Baseline up to Day 21
Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Postdose
Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety ECG at Least Once Postdose
Time frame: Baseline up to Day 8
Part 1: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety Electroencephalogram (EEG) Measurements at Least Once Postdose
Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Part 2: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety EEG Measurements at Least Once Postdose
Time frame: Baseline up to Day 18
Part 1: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).
Time frame: Cohort 1-5: Baseline up to Day 7; Cohort 6: Baseline up to Day 8
Part 2: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS
Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).
Time frame: Baseline up to Day 21
Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 1
Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints (up to 120 hours) post-dose
Part 2: Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 6
Time frame: Day 6 pre-dose at multiple timepoints (up to 24 hours) post dose
Part 2: Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-653
Time frame: Day 18 pre-dose and at multiple time points (up to 24 hours) post dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 1
Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose
Part 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 18
Time frame: Day 18 pre-dose and at multiple time points (up to 24 hours) post dose
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-653
Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-653
Time frame: Part 1 Cohort 1-5: Day 1 pre-dose and at multiple timepoints (up to 144 hours) post-dose; Part 1 Cohort 6: Day 1 pre-dose and at multiple timepoints (up to 168 hours) post-dose; Part 2: Day 1 pre-dose and at multiple timepoints up to 120 hours) post-dose
Part 2: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-653
Time frame: Days 6 and 18 pre-dose and at multiple timepoints (up to 24 hours) post-dose
Participants took part in the study at 1 investigative site in United Kingdom from 26 August 2015 to 23 September 2017.
| Milestone | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 6 | 6 | 6 | 6 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 6 | 6 | 6 | 5 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| percentage of participants | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg |
|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) | 41.7 | 66.7 | 66.7 | 50.0 | 83.3 | 33.3 | 33.3 |
| percentage of participants | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|
| Part 2: Percentage of Participants Who Experience at Least One TEAE | 50.0 | 50.0 | 50.0 | 100.0 | 33.3 | 50.0 |
| percentage of participants | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg |
|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| percentage of participants | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|
| Part 2: Percentage of Participants Who Discontinued the Treatment Due to an AE | 0 | 0 | 0 | 0 | 16.7 | 0 |
| percentage of participants | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg |
|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose | 0 | 16.7 | 0 | 16.7 | 0 | 0 | 0 |
| percentage of participants | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|
| Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose | 0 | 33.3 | 0 | 0 | 0 | 16.7 |
| percentage of participants | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg |
|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose | 75.0 | 50.0 | 100.0 | 66.7 | 83.3 | 83.3 | 66.7 |
| percentage of participants | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|
| Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose | 90.0 | 100.0 | 100.0 | 100.0 | 83.3 | 83.3 |
| percentage of participants | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg |
|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Postdose | 66.7 | 33.3 | 33.3 | 50.0 | 0 | 33.3 | 50 |
| percentage of participants | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|
| Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety ECG at Least Once Postdose | 40.0 | 50.0 | 50.0 | 16.7 | 50.0 | 16.7 |
| percentage of participants | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg |
|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety Electroencephalogram (EEG) Measurements at Least Once Postdose | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| percentage of participants | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|
| Part 2: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety EEG Measurements at Least Once Postdose | 0 | 0 | 0 | 0 | 0 | 0 |
Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).
| participants | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg |
|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 1 | 3.5985 ± 14 | 10.2220 ± 15 | 26.9733 ± 10 | 44.9430 ± 13 | 68.8039 ± 16 | 123.6462 ± 21 | 2.8630 ± 23 | 7.7786 ± 12 | 28.0546 ± 23 | 41.0028 ± 24 | 76.0656 ± 27 |
| ng/mL | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|
| Part 2: Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 6 | 3.0485 ± 11 | 9.9202 ± 16 | 33.4862 ± 31 | 49.2842 ± 21 | 78.8995 ± 32 |
| ng/mL | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|
| Part 2: Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-653 | 7.6221 ± 29 | 23.9972 ± 31 | 97.2781 ± 28 | 140.4824 ± 37 | 223.3637 ± 53 |
| hours | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 1 | 1.250 (1.00 to 1.50) | 2.500 (1.00 to 3.00) | 1.750 (1.00 to 10.07) | 2.750 (1.00 to 12.10) | 5.500 (1.50 to 12.00) | 5.050 (1.00 to 10.03) | 1.250 (1.00 to 8.13) | 4.000 (1.00 to 6.00) | 1.500 (1.00 to 6.00) | 5.000 (3.00 to 6.08) | 4.508 (1.00 to 12.12) |
| hours | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|
| Part 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 18 | 2.500 (1.50 to 6.00) | 4.500 (2.00 to 12.00) | 4.000 (1.00 to 6.17) | 3.050 (1.00 to 10.00) | 3.000 (1.50 to 8.00) |
| nanogram*hour per milliliter (ng*hr/mL) | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-653 | 122.9927 ± 24 | 539.0930 ± 34 | 1310.5344 ± 23 | 2247.5468 ± 29 | 4264.3612 ± 37 | 7755.4570 ± 34 | 115.5869 ± 22 | 382.2871 ± 28 | 1417.0994 ± 31 | 1810.5437 ± 42 | 4065.9350 ± 54 |
| ng*hr/mL | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-653 | 143.6521 ± 29 | 596.5323 ± 43 | 1419.4306 ± 26 | 2536.8525 ± 35 | 4932.8519 ± 48 | 8413.1768 ± 40 | 129.5373 ± 26 | 448.9862 ± 36 | 1773.6365 ± 40 | 2027.7989 ± 56 | 5066.5536 ± 69 |
| ng*hr/mL | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|
| Day 6 | 51.0759 ± 19 | 159.9789 ± 16 | 578.9157 ± 26 | 778.2945 ± 13 | 1485.5059 ± 39 |
| Day 18 | 144.7834 ± 32 | 477.3427 ± 38 | 1901.4065 ± 24 | 2747.5976 ± 42 | 4144.0176 ± 60 |
Treatment-emergent suicidal ideation or behavior compared to baseline will be measured by an increase in suicidal ideation category (1-5 on the C-SSRS) or suicidal behavior category (6-10 on the C-SSRS) during treatment from the maximum suicidal ideation/behavior category at baseline, or any suicidal ideation/behavior during treatment if there is none at baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (1: wish to be dead; 2: non-specific active suicidal thoughts; 3: active suicidal ideation with any methods (not plan) without intent to act; 4: active suicidal ideation with some intent to act, without specific plan; 5: active suicidal ideation with specific plan and intent) and suicidal behavior (6: actual attempt; 7: interrupted attempt; 8: aborted attempt; 9: preparatory acts or behavior; 10: suicidal behavior).
| participants | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|
| Part 2: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 14 in Part 1 and Day 31 in Part 2. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Cohorts 1-6: Pooled Placebo | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Part 1 Cohort 1: TAK-653 0.3 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1 Cohort 2: TAK-653 1 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1 Cohort 4: TAK-653 5 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part 1 Cohort 5: TAK-653 9 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 1 Cohort 6: TAK-653 18 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2 Cohorts 1-5: Pooled Placebo | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Part 2 Cohort 1: TAK-653 0.3 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 2 Cohort 2: TAK-653 1 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 2 Cohort 3: TAK-653 3 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part 2 Cohort 4: TAK-653 6 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part 2 Cohort 5: TAK-653 9 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Event | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/12 | 1/6 | 1/6 | 1/6 | 1/6 | 2/6 | 0/6 | 1/10 | 1/6 | 2/6 | 3/6 | 1/6 | 1/6 |
| DizzinessNervous system disorders | 3/12 | 0/6 | 2/6 | 2/6 | 2/6 | 0/6 | 1/6 | 1/10 | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 |
| PresyncopeNervous system disorders | 0/12 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 |
| PalpitationsCardiac disorders | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Sinus tachycardiaCardiac disorders | 0/12 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| NauseaGastrointestinal disorders | 1/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/10 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 |
| Catheter site phlebitisGeneral disorders | 0/12 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| Catheter site related reactionGeneral disorders | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Influenza like illnessGeneral disorders | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Seasonal allergyImmune system disorders | 0/12 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
The safety analysis set included all participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 10 | 6 | 6 | 6 | 6 | 6 | 88 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Male | 10 | 5 | 5 | 6 | 6 | 6 | 6 | 10 | 6 | 6 | 6 | 6 | 6 | 84 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Not Hispanic or Latino | 12 | 6 | 5 | 6 | 6 | 6 | 5 | 10 | 6 | 6 | 6 | 5 | 6 | 85 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 8 |
| White | 8 | 6 | 4 | 6 | 6 | 4 | 5 | 7 | 4 | 4 | 5 | 6 | 4 | 69 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 10 | 6 | 6 | 6 | 6 | 6 | 88 |
| Smoking Classification(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Never smoked | 10 | 4 | 5 | 4 | 4 | 4 | 4 | 6 | 4 | 4 | 4 | 5 | 4 | 62 |
| Ex-smoker | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 2 | 26 |
| Female Reproductive Status(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgically sterile | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Female of childbearing potential | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Caffeine Consumption(Participants) | Part 1 Cohorts 1-6: Pooled Placebo | Part 1 Cohort 1: TAK-653 0.3 mg | Part 1 Cohort 2: TAK-653 1 mg | Part 1 Cohort 3: TAK-653 3 mg+TAK-653 3mg | Part 1 Cohort 4: TAK-653 5 mg | Part 1 Cohort 5: TAK-653 9 mg | Part 1 Cohort 6: TAK-653 18 mg | Part 2 Cohorts 1-5: Pooled Placebo | Part 2 Cohort 1: TAK-653 0.3 mg | Part 2 Cohort 2: TAK-653 1 mg | Part 2 Cohort 3: TAK-653 3 mg | Part 2 Cohort 4: TAK-653 6 mg | Part 2 Cohort 5: TAK-653 9 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Had caffeine consumption | 8 | 6 | 3 | 4 | 5 | 6 | 5 | 9 | 4 | 4 | 4 | 4 | 4 | 66 |
| Had no caffeine consumption | 4 | 0 | 3 | 2 | 1 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Aug 2015 to primary completion in Sep 2017, 24 months.
Results were first posted in Feb 2019, 1 year 4 months after primary completion.
Of 28 industry-sponsored phase 1 interventional studies under Depressive Disorder, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 6. This study's 24 months is above that.
Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 1 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osavampator